Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $103.31 USD
Change Today -3.04 / -2.86%
Volume 244.9K
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

gw pharmaceuticals -adr (GWPH) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/25/15 - $133.98
52 Week Low
10/16/14 - $58.16
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GW PHARMACEUTICALS -ADR (GWPH)

gw pharmaceuticals -adr (GWPH) Details

GW Pharmaceuticals plc, a biopharmaceutical company, together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines. It operates in three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company primarily offers Sativex, an oromucosal spray for the treatment of multiple sclerosis symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. In addition, the company’s product pipeline includes an orphan childhood epilepsy program, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. It has a strategic alliance with Otsuka Pharmaceutical Co., Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Salisbury, the United Kingdom.

313 Employees
Last Reported Date: 08/6/15
Founded in 1998

gw pharmaceuticals -adr (GWPH) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 567.8K GBP
Founder, Executive Chairman and Chairman of N...
Total Annual Compensation: 696.1K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 389.8K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 421.8K GBP
Chief Medical Officer and Executive Director
Total Annual Compensation: 475.3K GBP
Compensation as of Fiscal Year 2014.

gw pharmaceuticals -adr (GWPH) Key Developments

GW Pharmaceuticals plc Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015

GW Pharmaceuticals plc announced unaudited consolidated earnings results for the third quarter and nine months ended June 30, 2015. For the quarter, revenue was £8,629,000, operating loss was £24,768,000, loss before tax was £24,743,000 and loss for the period was £21,425,000 or 8.5 pence per diluted share against revenue was £7,611,000, operating loss was £7,311,000, loss before tax was £7,307,000 and loss for the period was £6,928,000 or 3.2 pence per diluted share for the same period a year ago. For the nine months, revenue was £22,945,000, operating loss was £38,571,000, loss before tax was £38,470,000 and loss for the period was £32,330,000 or 13.4 pence per diluted share against revenue was £22,626,000, operating loss was £17,937,000, loss before tax was £17,916,000 and loss for the period was £14,941,000 or 7.4 pence per diluted share for the same period a year ago. Net cash outflow from operating activities was £24,090,000 against £2,406,000 a year ago. Purchases of property, plant and equipment was £14,136,000 against £4,761,000 a year ago.

GW Pharmaceuticals plc Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy

GW Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for a proprietary intravenous form of cannabidiol (CBD) to treat Neonatal Hypoxic-Ischemic Encephalopathy, or NHIE. In addition, the European Medicines Agency (EMA) has granted orphan designation for the same product to treat perinatal asphyxia, an alternate term that describes the same condition as NHIE, for which GW has already received Orphan Drug Designation from the FDA. There are currently no approved medicines in Europe or the U.S. specifically indicated for NHIE or perinatal asphyxia. NHIE and perinatal asphyxia are forms of acute or sub-acute brain injury due to asphyxia caused during the birth process and resulting from deprivation of oxygen during birth (hypoxia). The incidence of these conditions is estimated to be approximately 12,000 to 24,000 cases per year in the United States and EU combined. Of these cases, 35% are expected to die in early life and 30% may suffer from permanent disability. The current standard of care for perinatal asphyxia patients is to induce whole-body hypothermia. This treatment is only available in specialized neonatal intensive care units and must be started within 6 hours of birth. Even if a patient is put into induced hypothermia there is still a significant rate of morbidity and mortality, with a meta-analysis of the available data revealing a 27% death rate. Among the patients who survive, 28% suffer from major neurodevelopment issues and 26% develop Cerebral Palsy. FDA's Fast Track program facilitates the development and review of drugs intended to treat serious conditions and fill an unmet medical need. A drug development program with Fast Track designation is afforded greater access to the FDA for the purpose of expediting the drug's development, review and potential approval to get important new drugs to the patient earlier. The EMA orphan designation is a status assigned to a medicine intended for use against a rare condition (prevalence of the condition in the European Union must not be more than 5 in 10,000) and allows a pharmaceutical company to benefit from incentives offered by the EU to develop a medicine for the treatment, prevention or diagnosis of a disease that is life-threatening or a chronically debilitating rare disease. These incentives can include reduced fees and protection from competition once the medicine is placed on the market.

GW Pharmaceuticals plc to Report Q3, 2015 Results on Aug 06, 2015

GW Pharmaceuticals plc announced that they will report Q3, 2015 results at 8:00 AM, US Eastern Standard Time on Aug 06, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GWPH:US $103.31 USD -3.04

GWPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cannabis Science Inc $0.04 USD +0.002
Medical Marijuana Inc $0.04 USD 0.0001
PharmaCyte Biotech Inc $0.10 USD -0.002
View Industry Companies

Industry Analysis


Industry Average

Valuation GWPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 48.2x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 50.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GW PHARMACEUTICALS -ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at